



Central Clinical School News

Creating the health professionals and researchers of tomorrow
CCS News Mar/Apr 2011

Medical research funding under threat of amputation



Photo: Jane Arthur. Researchers out en masse at the rally

Monash University academics attended the rally on Tuesday 12 April in Melbourne against the proposed \$400M cut to the NH&MRC budget in the next Commonwealth Budget, being handed down next month.

Prime Minister Julia Gillard has declined to comment on the cuts or whether they are taking place. Four thousand attended the Melbourne rally, and thousands more turned out nationally.

See www.youtube.com/watch?v=O-zWBB-3nLs&feature=youtube_gdata_player for 'Discoveries need dollars'.

Quick links

- [Medical research funding under threat](#)
- [Message from Professor Steve Jane, Head, Central Clinical School](#)
- [Partnership for improved HIV health care](#)
- [New lupus therapy](#)
- [Monash HIV research recognised](#)
- [2011 International Day of Immunology](#)
- [Profile: Surgery PhD student Elena Shek](#)
- [Focus on Monash Microimaging facilities at AMREP](#)
- [Recent Media mentions](#)
- [New CCS Staff](#)
- [Hub staff](#)
- [Useful links and contacts](#)
- [Forthcoming Events](#)

Message from Professor Steve Jane, Head, Central Clinical School

As you are all aware, the major issue confronting us in our professional sphere is the cuts to Medical research expenditure proposed by The Prime Minister. Although, as scientists, fiscal responsibility is something we all appreciate, we would question the wisdom of targeting the medical research budget for cost savings. This is particularly germane in the context of an ageing population and increasing costs of health delivery. The flow on effects of such budget cuts would be catastrophic and far reaching at multiple levels including: job losses, predominantly affecting our young upcoming scientists; loss of career structures with contraction of Fellowship programs; expatriation of our scientific future to more supportive climates; increased cost of health care delivery and pharmaceuticals as Australia loses its stake in the production line; and most significantly, loss of hope for patients and their families and loved ones burdened with diseases that are the subject of our efforts – diabetes, heart disease, cancer, asthma, leukemia, cystic fibrosis, HIV – to mention just a few that are particularly relevant in our Institutes.

I urge you to be outspoken on this issue. The School has circulated a petition that will be tabled in Federal Parliament – a petition that I trust will carry the signatures of researchers, clinicians, patients and all other Australians that realise that hope is a cornerstone of the human condition.

Partnership for improved HIV health care



Left-right: Dr Julian Elliott, Mr Andrew Way and Professor Sharon Lewin

Professor Sharon Lewin of the Central Clinical School at Monash University and Director, Infectious Diseases Unit, Alfred Hospital together with Dr Julian Elliott, Head, Clinical Research, Infectious Diseases Unit, Alfred Hospital have recently been awarded \$1.5M for an NHMRC Partnership grant. They will perform a randomised clinical trial of a novel self management program for the long term management of HIV infection and its complications.

HealthMap partners include The Alfred Hospital, which will contribute \$1 million from its research trust funds and the National Association for People Living with HIV/AIDS and Australasian Society for HIV Medicine, which together are making an in-kind contribution of over \$500,000. Additional research partners are the University of Melbourne, Flinders University, Deakin University, La Trobe University and Departments of Health in Victoria and NSW.

Professor Lewin and Dr Elliott will develop an online platform, called HealthMap, to support partnerships between health care workers and people with HIV, enabling patients to better manage their own health. Professor Lewin said, "Currently there are approximately

20,000 Australians living with HIV, 6500 in Victoria. The Alfred Hospital runs the Victorian HIV Service, a state wide referral service which sees 80 per cent of the Victorian HIV patients. Managing HIV is very different in 2011 to twenty years ago. Often the virus is easy to control with anti HIV drugs but patients face a whole range of other complications related to side effects of the drugs, chronic inflammation and ageing. So we need a new model of care for managing HIV-infected patients in both hospital and community based settings."

Dr Elliott said, "For many years we have known that people with chronic conditions achieve better outcomes when encouraged and supported to take greater control of their own health. There are now increasing opportunities to use technology in these programs making them more accessible and cost effective. However, we are only just beginning to understand the best ways to design these programs and as yet there is no program available for people with HIV."

People living with HIV experience an increased incidence and earlier onset of several chronic conditions often associated with ageing, including cardiovascular disease, dementia, cancers, osteoporosis and kidney and liver disease.

This has increased the complexity of care and often patients are seeing their primary HIV doctor in addition to multiple specialists.

After a two year period in which the HealthMap platform will be developed and piloted, the randomised trial will recruit 1300 patients through 24 clinics in NSW and Victoria and will run over three years. The clinical sites will be randomised, half to have immediate access to the intervention and half to receive the intervention after completion of the trial.

CEO for The Alfred, Mr Andrew Way, said, "We're very pleased with this partnership. We are uniquely positioned to lead the way for better models of care for patients with HIV which are patient centred and focus on prevention of chronic disease. Although the trial will be performed in Victoria and NSW, we anticipate that the findings will be translated to many other clinical settings around the world and to other patient groups at risk of chronic disease."

www.monash.edu.au/news/show/healthmap-directing-hiv-patients-to-better-health-outcomes

New Lupus therapy

Professor Fabienne Mackay (pictured), Head of the Department of Immunology at Monash University, has been researching the major mechanisms within the immune system involved in lupus for several years.

Lupus is an autoimmune inflammatory disease affecting about five million people worldwide. An autoimmune problem is one where the body's immune system attacks the body itself. In the case of lupus, the immune system attacks connective tissue in the joints, lungs, kidneys and heart, causing joint and skin diseases in most patients, and organ and blood disorders in about half of lupus sufferers. The indigenous Australian population suffers from lupus at a rate double that of a non-Aboriginal population.

The pharmaceutical group GlaxoSmithKline (GSK) and Human Genome Sciences Inc. (HGS) have developed a new medication, Benlysta, which was approved by the US Food and Drug Authority for release last month. This is great news for lupus sufferers, as there has been no medication developed for lupus in over fifty years. The drug is currently under review by the Australian Therapeutic Goods Authority.

Professor Mackay says, "We believe that a number of factors, both genetic and environmental, are involved in the development of lupus. Lupus itself is

not one single thing, there being a number of different types of lupus. The one I've been investigating is the most common and most serious form of lupus called systemic lupus erythematosus (SLE).

"My work, performed in the group headed by Dr Jeffrey Browning at BiogenIdec Inc in Boston, USA identified a new natural factor named 'BAFF' (or BLYS) in collaboration with the group of the late Professor Jurg Tschopp in Lausanne Switzerland. 'BAFF' stands for B cell Activating Factor. B cells make antibodies for invaders such as bacteria or other foreign bodies such as pollen. BAFF helps B cells survive, which is a good thing. But if there is too much BAFF, then there can be an overproduction of B cells and they hang about for longer than they should – in particular B cells that are normally meant to die because they are harmful. Autoimmunity will be initiated, and this is how the immune system ends up attacking the body's own cells."

Professor Mackay was the first to show that the overproduction of BAFF was driving lupus. In a follow up study, elevated levels of BAFF were discovered in patients with a number of autoimmune diseases including lupus, rheumatoid arthritis and Sjögren's syndrome. "This was an exciting discovery as it implied that if BAFF production can be blocked, the entire cascade resulting in autoimmune disease could be prevented."

Additionally, her data showed that autoimmune disease driven by excessive production of BAFF was rather unusual and due to the production of pathogenic autoantibodies. This key discovery in animal models about the mechanism used by BAFF to drive disease was paralleled by a very similar observation in lupus patients.

GSK designed their clinical trials in line with the insights from Professor Mackay's experimental data, as they specifically selected lupus patients with autoantibodies to test a new treatment blocking BAFF.

"In order to successfully treat a complicated medical problem, we have to understand first how a healthy biological system works. Once we know that, then we can understand how it fails to work, causing sickness. Only then can we systematically investigate and develop effective therapies.


"I am very pleased to have created the platform of knowledge from which effective therapies can springboard. In particular, I have long been concerned about the higher incidence of this disease and associated morbidity within indigenous Australians populations and the limited arsenal of therapies, many very toxic, and it is wonderful news that a medication has been developed which may be able to help them."

www.monash.edu.au/news/show/monash-research-leads-to-first-lupus-breakthrough-in-50-year



Professor Fabienne Mackay

Monash HIV research recognised



Left-right: Dr Suha Saleh and Dr Megan Crane

Two Monash post-doctoral scientists have received prestigious fellowships from the American Foundation for AIDS Research (amfAR).

Dr Megan Crane and Dr Suha Saleh are Research Fellows in the HIV and Hepatitis Immunopathogenesis Laboratory, co-headed by Professor Sharon Lewin and Dr Paul U. Cameron in the Department of Medicine at Monash University. Professor Lewin is the Director of the Infectious Diseases Unit, Alfred Hospital; Professor of Medicine at Monash and co-head, Centre for Virology, Burnet Institute.

Dr Crane has been awarded a two year Krim Fellowship from amfAR for her project, LPS, immune activation and liver disease in HIV-HBV co-infection. Dr Crane is the first Australian scientist to receive this award, worth US \$125,000.

Dr Crane began working with Professor Lewin in 2007 after finishing her PhD at Monash Institute of Medical Research, in the

immunology of the male reproductive tract. She is now collaborating closely with clinicians at The Alfred Hospital Infectious Diseases Unit.

"HIV affects the immune cell barrier of the gut, making it more permeable to bacteria, thereby allowing an increased load of bacterial products into the circulation. This places a greater burden on the liver, which clears pathogens and impurities. When people are infected with both HIV and Hepatitis B (HBV), they progress to liver disease faster than people infected only with hepatitis B,"

"We believe that a greater bacterial burden promotes inflammation in the liver and this is the underlying cause of accelerated liver disease in people with both HIV and HBV. There are striking similarities with respect to inflammation in the liver in these people and in people suffering from diseases of chronic inflammation such as rheumatoid arthritis. It is possible that drugs currently used for managing inflammation might also be used for HIV-HBV infected patients," Dr Crane said.

Dr Suha Saleh in the Lewin/Cameron Laboratory (HIV and Hepatitis Immunopathogenesis) has also been awarded a two year fellowship, worth a total of US\$125,000 for her project as part of a recent call for medical research projects relevant to exploring the mechanisms for HIV persistence and the potential for HIV eradication.

The fellowship will support Dr Saleh's work to identify the mechanisms of how chemokines help HIV to get into resting cells and establish latent infection.

"HIV is a clever virus, able to transform and hide itself inside healthy cells. The main reservoir, or hiding place, is a cell type in the immune system called a resting memory CD4+T cell. HIV can't be eradicated with antiviral drugs, as the drugs do not recognise the virus particles inside resting cells. Resting memory cells 'remember' previous infections, and can be activated for attack if those same pathogens are detected again. These infected resting cells are very long lived, as we are. Hence, once infected with HIV, they are time bombs, as when the cells become active, HIV will also become active even though only one in a million resting cells are infected. Our group has recently shown how these resting cells can be infected in the laboratory.

"My research is investigating the mechanism of how HIV enters a resting cell. We have found that proteins called chemokines which are involved in guiding the movement of infection fighting T cells around the body, are also critical in allowing latent infection in resting cells to be established. If we can identify the exact pathways which lead to latent infection, we will be in a position to develop novel therapies to block or reverse latent HIV infection," Dr Saleh said.

www.monash.edu.au/news/show/monash-hiv-research-recognised

2011 International Day of Immunology

School Project: The Body at War

Dr Charles Hardy in the Department of Immunology, Dr Meredith O'Keeffe from the Burnet Institute, as well as others from the Day Of Immunology committee, have developed a competition for primary school children as part of the International Day of Immunology activities. Please send on to primary school teachers!

Win Cool Stuff for your Classroom!!!

To raise awareness of the immune system and immunology research in Australia the Victorian branch of the Australasian Society for Immunology is running a competition in Victorian Primary Schools.

Instructions to enter: Imagine that you have just caught the flu. The cells in your immune system have mounted a major defence and your body is now at war to fight this virus. Represent this battle between the cells in your immune system and the virus as either:
1. A collage (Grades 1-3)
2. A digital story OR short video (Grades 4-6)
Classes enrolling will be given info packs describing immune cells and how they work. Stories and videos should be brief, i.e. a maximum of 5 minutes. Prizes awarded for the best entries in each category: 'Juniors' (Grades 1-3) and 'Seniors' (Grades 4-6). The competition is open to all Victorian Primary Schools.

Prizes:
1st - Either: 3 iPod Touch OR 4 Flip video cameras OR 1 Compaq cq3350 desktop computer and 20 inch LCD monitor plus Fuji Finepix digital camera with video. A commemorative trophy.
2nd - Australian Geographic prize packs of magazines, books, posters & toys, binoculars, globe and plasma ball.
3rd - Book vouchers

Closing date: Friday 10th June 2011, 5pm. Winners will be announced Thursday 30th June and will be personally contacted. Entries should include school contact details, class and year level (either Grades 1-3, or Grades 4-6) and should be emailed OR posted to Dr Meredith O'Keeffe, Burnet Institute, 85 Commercial Rd, Melbourne, 3004. Meredith@burnet.edu.au
Thanks to sponsors: Monash University, Burnet Institute, ASI, Officeworks, Australian Geographic, Village Roadshow, Becton Dickinson, Interpath Services.
Enquiries: charles.hardy@monash.edu or Meredith@burnet.edu.au

Student Profile – Get to know Elena Shek



Department of Surgery
Doctoral student

Campus: Alfred

Year level:
first year PhD

Why did you choose Monash?

Well, it's a long story – it's really the Tao of life. I couldn't really say I 'chose' Monash, it's more that I was following my instincts and intellectual curiosity, opportunities arose and this is where I now am.

Tell us about yourself and how you chose your educational path

I was born in Hungary to a Ukrainian mother and a Polish father, and grew up in the Soviet Union with Russian as my first language (I can get by in Polish and Ukrainian). Education was highly regarded then and very much emphasised in our communist society. Medicine under Communism was rated much as a service industry, so I did medicine primarily out of the wish to help other people. Once graduated, I was assigned to work in an area affected by the Chernobyl nuclear plant accident. I was not assured of safety

so I didn't go and my medical career was put on hold. In the mean time Glasnost was happening and Soviet Union was opening its borders. I was amongst the first Russians who had a very rare opportunity to visit the UK, so I went. I fell in love with both the country and its people. I stayed in England, married and had three children.

How did you move into postgraduate study?

When my husband and I decided to part our ways, I took the children and moved to India. I believed that my kids would get good quality education while experiencing life in a different culture. I settled in Bangalore, got work teaching and looked for opportunities to resume my medical career. I was fortunate to be accepted at the Institute of Clinical Research (India) to do a Masters degree in Clinical Research. India was a good move, as it was easy for me to run the family while doing studies, research and travelling a lot. I had 'hands on' support from many people around me.

While doing my course in Bangalore I became really interested in Evidence Based Medicine and Cochrane systematic reviews. I got involved in working with the Cochrane Schizophrenia Group in Nottingham, UK and it was at the Joint Colloquium of The

Campbell and Cochrane Collaborations in Colorado, that met Professor Russell Gruen, now my supervisor here at Monash.

What is your research topic?

My research topic is about 'Promoting evidence-based care through optimal use of evidence resources', in particular in the area of neurotrauma. I think medical decisions should be made on the basis of the best available evidence. But in reality, we're all human, and doctors make decisions on anecdotal evidence, what has worked before, which drug companies have the most convincing publicity, patients requesting particular medications and so on. I'm interested in the reality of the process of uptake of best evidence by medical practitioners, and how to facilitate the knowledge transfer from research to practice.

How do you like Australia?

I've only been here since early February, but my children, while they enjoyed India, are loving it here and have settled well into the new schools. I'm finding people are very friendly and helpful and I'm glad to be here, although I miss my maid Manju I used to have in India! This new stage of my life is both challenging and fun, and I am looking forward to it.

Recent Media Mentions



Associate Professor Cristina Morganti-Kossmann
Photo credit: Herald Sun.

Cristina Morganti-Kossmann Surgery/ NTRI, on NTRI's contribution to a global effort looking at whether erythropoietin – otherwise known as EPO – can boost the brain's recently discovered ability heal itself.

14/03/2011

<http://news.smh.com.au/breaking-news-national/a-drug-to-help-brain-heal-itself-20110314-1bu0j.html>

www.sbs.com.au/news/article/1499872/A-drug-to-help-brain-heal-itself

<http://news.ninensn.com.au/health/8223709/a-drug-to-help-brain-heal-itself>

<http://au.news.yahoo.com/thewest/lifestyle/a/-/health/9007637/drug-may-help-brain-heal-itself/>

<http://au.news.yahoo.com/thewest/a/-/national/9007509/a-drug-to-help-brain-heal-itself/>

www.bia.net.au/index.php?option=comcontent&view=article&id=306:a-drug-to-help-brain-heal-itself-&catid=10:news&Itemid=22

www.sbs.com.au/news/article/1499872/headline

http://digg.com/news/science/a_drug_to_help_brain_heal_itself

web.lawampm.com/blog/traumatic-brain-injury/?p=67

www.heraldsun.com.au/news/victoria/drug-may-help-heal-brain-injuries/story-e6frf7kx-1226021339744

Professor Sharon Lewin, Department of Medicine on HealthMap: a cluster randomised trial of interactive self-care plans to prevent and manage chronic conditions by people living with HIV. NH&MRC Partnership \$1.5M grant. See feature this issue.

22/03/2011

www.nhmrc.gov.au/node/30442

Dr Lesley Braun, Department of Surgery and Research pharmacist, The Alfred, on community pharmacists deciding if they are to embrace the changes necessary to improve substantially the 'nonprescription' services they offer. Additional mention: Colin Chapman, Emeritus professor, Monash University, and Professorial fellow, Australian Health Workforce Institute, University of Melbourne

1/04/2011

Australian Prescriber Magazine. www.australianprescriber.com/magazine/34/2/34/5

Professor JV Rosenfeld, Department of Surgery on Monash's Bionic Vision project, of which Surgery is a part. This piece features Tony Burkitt.

1/04/2011

www.smh.com.au/technology/technology-news/the-bionic-eye-we-have-the-technology-the-microchip-has-arrived-20110331-1cngn.html

Focus on Monash Micro Imaging Facility at AMREP



Left-Right: Dr Iska Carmichael, Imaging Associate; Mr Stephen Cody, Imaging Research Fellow and Manager; and Dr Candida da Fonseca Pereira, Head, Burnet Cell Imaging Facility and Research Fellow, Monash Micro Imaging, Monash University..

Monash Micro Imaging has established a node at AMREP to manage the core imaging resources of Baker IDI Heart and Diabetes Institute, the Burnet Institute and Monash University Central Clinical School. MMI@AMREP coordinates and facilitates microscopy developments, and is responsible for microscopy training and research support.


Currently MMI@AMREP manages three confocal, and several conventional fluorescence microscopes within PC2 laboratories. There is also a dedicated deconvolution microscope within a PC3 facility if required. MMI@AMREP staff are available to help with experimental design, and techniques such as; live and fixed cell imaging, time-lapse, 3D, high resolution of large areas, fluorescence, brightfield, phase, DIC, ion imaging such as Ca²⁺ and pH.

Training on microscopes will be conducted on request, and is usually coupled with a discussion on the imaging requirements of the research project. This ensures that the training is targeted to the needs of the project, and that the experimental design is appropriate. Training seminars and workshops are also conducted to help broaden the understanding of imaging. MMI@AMREP staff are keen to assist when purchasing a new microscope, ensuring researchers order the right technology to suit their needs and have expertise in negotiating discounted pricing.

MMI@AMREP has an office in Lower Ground, Baker IDI, a Monash office on the sixth floor of Burnet Tower and a Burnet office on level one of the Burnet tower.

Contact Stephen Cody for microscopy related issues, including training, research support, pricing and quotations, instrument demonstrations and promotions, new technology; and for updated Equipment List. Email: stephen.cody@monash.edu Telephone: 9905 3014

Additionally, the Victorian Platform Technologies Network (www.find.platformtechnologies.org) and the Victorian Bioportal (www.vicbioportal.org) will give researchers current and complete information about Victorian equipment resources.



Bovine pulmonary artery endothelial (BPAE) cells stained with a combination of fluorescent dyes. Mitochondria were labelled in green, F-actin labelled in red, and blue labelled nuclei. This image was composed of three sequentially collected images using a black and white camera on a conventional fluorescent microscope (Olympus BX61). Image by MMI.

New CCS Staff Jan–March 2011

Ms Leanda Griffin

Teaching and Research
Undergraduate Teaching
Alfred Hospital

Dr Alexander Agrotis

Research
Immunology Alfred Hospital

Ms Dilinie Herbert

Teaching and Research
Centre for Study of Ethics

Dr Mark Guthridge

Research
Australian Centre for Blood Diseases

Ms Lingli Li

Research
Aust Ctr for Blood Diseases

Dr Patricia Walker

Teaching and Research
Australian Center for Blood Diseases

Dr Mhairi Maxwell

Research
Immunology Alfred Hospital

Dr Zhiyong Yang

Research
Medicine Alfred Hospital

Ms Claire Petitjean

Research
Australian Center for Blood Diseases

Dr Loretta Piccenna

Research
Surgery Alfred Hospital

Ms Tracy Phan

Other Immunology
Alfred Hospital

Alfred Centre Hub Staff:

Research and Revenue website

Research and Revenue Hub
Hotline #30990

Email: researchandrevenues-alfred@monash.edu

<http://intranet.monash.edu.au/finance/revenue-accounting/index.html>

Ben Norman

Research and Revenue Manager
#30639

Rowena Van Essen

Research and Revenue Accountant
#30963

Finance Officer (vacant) #30462**Purchasing to Payment (P2P)**

Email: ac-financehub-1.med-ac-financehub-1@monash.edu

website: <http://intranet.monash.edu.au/finance/purchase-to-payment/index.html>

Stan Stasinopoulos

P2P Supervisor #30141

Glenis Rickard

P2P Purchasing Officer #30172

Glen Wescott

P2P Stores Officer #30014

Evelyn Braganza

P2P Purchasing Officer #30719

IT AMREP

Email: tsg-amrep-1@monash.edu.au

TSG AMREP services,
see <http://tsg-amrep.med.monash.edu.au/>

Colin Fee

Contact through AMREP TSG job desk
http://jobdesk.monash.edu.au/login/index.cfm?jobdesk_id=35

David Khuu**Martin Treasure****Greg Johnson****Human Resources****Jacinta Pope**

CCS Senior HR Business Partner
#30614

Natangaline Naidu

CCS HR Client Support Officer #30987

Renay Wallis

SPHPM HR Business Partner #30562

Lauren Komel

SPHPM HR Client Support Officer
#30986

Shwetha D'Souza

SPHPM HR Client Support Officer
#30363

Useful links and contacts

**CCS Departmental and
Special Interest Newsletters**

Department of Immunology:
<http://med.monash.edu.au/med/immunology/newsletters.html>

Department of Surgery:
<http://www.med.monash.edu.au/surgery/alfred/newsletters/index.html>

CCS Early Career Researchers (ECR):
<http://ebulletin.med.monash.edu.au/newsletter.cfm?issueNo=406#8>

Grant opportunities

Biomedical and medical grant schemes:
<http://www.alfredresearch.org/funding/calendar.htm>

Monash Research Office Funding:
<http://www.monash.edu.au/researchoffice/funding.php>

Monash Research Office GrantsWatch:
<http://monash.edu/researchoffice/grantswatch/>

Faculty eBulletin
<http://ebulletin.med.monash.edu.au/index.cfm>

Admin information

Photos of CCS staff and students are stored in the V drive, at: V:\school\Photos\Staff- individual and groups.

These pics are already uploaded to the JD above. See sample below pictured left to right, top to bottom: Dilinie Herbert, Lingli Li, Mhairi Maxwell, Loretta Piccenna



Forthcoming Events

All welcome to the following CCS based events, table of dates for May/June below.

- **PhD confirmations:** coordinated by Gladys Britto, Gladys.britto@monash.edu
Telephone: 9903 0027
- **Early Career Researcher seminars:** The Central Clinical School Early Career Researcher (ECR) 2011 seminar series is fortnightly on Thursdays, 1–2 pm, Level 5 lecture theatre, Alfred Centre. It showcases the research of postdoctoral fellows and final year PhD students within the School. To participate in the series, please email ecr.amrep@monash.edu.
- Department of Immunology seminars: As advised by email.

Date	Time	Venue	Topic	Speaker
4 May	1–2 pm	Lecture Theatre, Level 5, Alfred Court	PhD seminar	JianXiong Chan (Progress) William Figgett (Progress)
9 May	4–5 pm	Lecture Theatre Level 5, Alfred Centre	AMREP Immunology Seminar	Associate Professor David Tarlington, Division of Immunology, WEHI. Topic TBA
11 May	1–2 pm	Lecture Theatre Level 5, Alfred Centre	PhD seminar	Jeanne LeMasurier (Progress) Inhibition of experimental asthma by ultra-fine nanoparticles
25 May	1–2 pm	Seminar Room 2, Level 5, Alfred Centre	PhD seminar	Amit Joglekar (Progress) Li Jaze (Baker IDI) Mechanisms of tolerance following
1 June	1–2 pm	Seminar Room 2, Level 5, Alfred Centre	PhD seminar	Chris Chan (Progress) The role of Natural Killer (NK) cell receptors in immunity and disease.
8 June	1–2 pm	Lecture Theatre Level 5, Alfred Centre	PhD seminar	Indzi Katik (Progress) Regulation of telomerase activity and telomere remodeling in lymphocytes
15 June	1–2 pm	Lecture Theatre Level 5, Alfred Centre	PhD seminar	Rohimah Mohamud, Effects of particles on lung antigen presenting cells: implication for asthma development and immuno-therapy
22 June	1–2 pm	Lecture Theatre Level 5, Alfred Centre	PhD seminar	Tara Bull (Progress) CCSP as a biomarker post lung transplantation: genetic predisposition, abundance and function
29 June	1–2 pm	Seminar Room 2, Level 5, Alfred Centre	PhD seminar	Yin Teng (Felicia) Yap (Progress) The Contribution of AGEs and the Receptors to Beta Cell Dysfunction

Contact Us

Editor/Writer: Julia Veitch
 Telephone: +61 3 99030026
 Email: Julia.veitch@monash.edu
 Send news items to: ccs.news@monash.edu